^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    favezelimab/pembrolizumab (MK-4280A)

    i
    Other names: MK-4280A, MK-4280/MK-3475, MK4280A, MK 4280A
    Associations

    News

    Trials
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: May 2026 --> Dec 2029
    Trial primary completion date
    |
    Lenvima (lenvatinib) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • raludotatug deruxtecan (DS-6000)
    15d
    KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=49, Completed, Merck Sharp & Dohme LLC | N=37 --> 49
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    17d
    Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (clinicaltrials.gov)
    P3, N=3500, Recruiting, Merck Sharp & Dohme LLC | N=1343 --> 3500
    Enrollment change
    |
    Lynparza (olaparib) • Lenvima (lenvatinib) • favezelimab/pembrolizumab (MK-4280A)
    18d
    KeyForm-010: Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (clinicaltrials.gov)
    P2, N=160, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion • Pan tumor
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • favezelimab/pembrolizumab (MK-4280A)
    23d
    Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (clinicaltrials.gov)
    P3, N=3500, Recruiting, Merck Sharp & Dohme LLC | N=1342 --> 3500
    Enrollment change
    |
    Lynparza (olaparib) • Lenvima (lenvatinib) • favezelimab/pembrolizumab (MK-4280A)
    29d
    KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=390, Completed, Merck Sharp & Dohme LLC | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    2ms
    KEYFORM-008: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) (clinicaltrials.gov)
    P2, N=203, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    gemcitabine • favezelimab/pembrolizumab (MK-4280A)
    3ms
    KeyForm-010: Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2027 --> Mar 2026 | Trial primary completion date: Mar 2027 --> Mar 2026
    Trial completion date • Trial primary completion date • Pan tumor
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • favezelimab/pembrolizumab (MK-4280A)
    4ms
    KEYMAKER-U06 substudy 06A: A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) (clinicaltrials.gov)
    P1/2, N=90, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
    4ms
    Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) (clinicaltrials.gov)
    P2, N=296, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    6ms
    KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=146, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=90 --> 146
    Trial completion • Enrollment change
    |
    Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
    6ms
    KEYFORM-008: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) (clinicaltrials.gov)
    P2, N=203, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial primary completion date
    |
    gemcitabine • favezelimab/pembrolizumab (MK-4280A)